119 related articles for article (PubMed ID: 26524858)
21. Molecular basis of FIR-mediated c-myc transcriptional control.
Cukier CD; Hollingworth D; Martin SR; Kelly G; Díaz-Moreno I; Ramos A
Nat Struct Mol Biol; 2010 Sep; 17(9):1058-64. PubMed ID: 20711187
[TBL] [Abstract][Full Text] [Related]
22. Anti-FIRs (PUF60) auto-antibodies are detected in the sera of early-stage colon cancer patients.
Kobayashi S; Hoshino T; Hiwasa T; Satoh M; Rahmutulla B; Tsuchida S; Komukai Y; Tanaka T; Matsubara H; Shimada H; Nomura F; Matsushita K
Oncotarget; 2016 Dec; 7(50):82493-82503. PubMed ID: 27756887
[TBL] [Abstract][Full Text] [Related]
23. c-myc suppressor FBP-interacting repressor for cancer diagnosis and therapy.
Matsushita K; Tomonaga T; Kajiwara T; Shimada H; Itoga S; Hiwasa T; Kubo S; Ochiai T; Matsubara H; Nomura F
Front Biosci (Landmark Ed); 2009 Jan; 14(9):3401-8. PubMed ID: 19273283
[TBL] [Abstract][Full Text] [Related]
24. The FBP interacting repressor targets TFIIH to inhibit activated transcription.
Liu J; He L; Collins I; Ge H; Libutti D; Li J; Egly JM; Levens D
Mol Cell; 2000 Feb; 5(2):331-41. PubMed ID: 10882074
[TBL] [Abstract][Full Text] [Related]
25. Dimerization of FIR upon FUSE DNA binding suggests a mechanism of c-myc inhibition.
Crichlow GV; Zhou H; Hsiao HH; Frederick KB; Debrosse M; Yang Y; Folta-Stogniew EJ; Chung HJ; Fan C; De la Cruz EM; Levens D; Lolis E; Braddock D
EMBO J; 2008 Jan; 27(1):277-89. PubMed ID: 18059478
[TBL] [Abstract][Full Text] [Related]
26. Quantitative characterization of the interactions among c-myc transcriptional regulators FUSE, FBP, and FIR.
Hsiao HH; Nath A; Lin CY; Folta-Stogniew EJ; Rhoades E; Braddock DT
Biochemistry; 2010 Jun; 49(22):4620-34. PubMed ID: 20420426
[TBL] [Abstract][Full Text] [Related]
27. The early response to DNA damage can lead to activation of alternative splicing activity resulting in CD44 splice pattern changes.
Filippov V; Filippova M; Duerksen-Hughes PJ
Cancer Res; 2007 Aug; 67(16):7621-30. PubMed ID: 17699766
[TBL] [Abstract][Full Text] [Related]
28. Alternative splicing of the tumor suppressor ASPP2 results in a stress-inducible, oncogenic isoform prevalent in acute leukemia.
Schittenhelm MM; Walter B; Tsintari V; Federmann B; Bajrami Saipi M; Akmut F; Illing B; Mau-Holzmann U; Fend F; Lopez CD; Kampa-Schittenhelm KM
EBioMedicine; 2019 Apr; 42():340-351. PubMed ID: 30952616
[TBL] [Abstract][Full Text] [Related]
29. Structural insights into a regulatory mechanism of FIR RRM1-FUSE interaction.
Ni X; Joerger AC; Chaikuad A; Knapp S
Open Biol; 2023 May; 13(5):230031. PubMed ID: 37253421
[TBL] [Abstract][Full Text] [Related]
30. BCLAF1 and its splicing regulator SRSF10 regulate the tumorigenic potential of colon cancer cells.
Zhou X; Li X; Cheng Y; Wu W; Xie Z; Xi Q; Han J; Wu G; Fang J; Feng Y
Nat Commun; 2014 Aug; 5():4581. PubMed ID: 25091051
[TBL] [Abstract][Full Text] [Related]
31. A neuron-specific splicing switch mediated by an array of pre-mRNA repressor sites: evidence of a regulatory role for the polypyrimidine tract binding protein and a brain-specific PTB counterpart.
Ashiya M; Grabowski PJ
RNA; 1997 Sep; 3(9):996-1015. PubMed ID: 9292499
[TBL] [Abstract][Full Text] [Related]
32. Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20.
He X; Ee PL; Coon JS; Beck WT
Clin Cancer Res; 2004 Jul; 10(14):4652-60. PubMed ID: 15269137
[TBL] [Abstract][Full Text] [Related]
33. Human tra2-beta1 autoregulates its protein concentration by influencing alternative splicing of its pre-mRNA.
Stoilov P; Daoud R; Nayler O; Stamm S
Hum Mol Genet; 2004 Mar; 13(5):509-24. PubMed ID: 14709600
[TBL] [Abstract][Full Text] [Related]
34. Hepatocyte growth factor enhances alternative splicing of the Kruppel-like factor 6 (KLF6) tumor suppressor to promote growth through SRSF1.
Muñoz Ú; Puche JE; Hannivoort R; Lang UE; Cohen-Naftaly M; Friedman SL
Mol Cancer Res; 2012 Sep; 10(9):1216-27. PubMed ID: 22859706
[TBL] [Abstract][Full Text] [Related]
35. Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis.
Stickeler E; Kittrell F; Medina D; Berget SM
Oncogene; 1999 Jun; 18(24):3574-82. PubMed ID: 10380879
[TBL] [Abstract][Full Text] [Related]
36. HP1 is involved in regulating the global impact of DNA methylation on alternative splicing.
Yearim A; Gelfman S; Shayevitch R; Melcer S; Glaich O; Mallm JP; Nissim-Rafinia M; Cohen AH; Rippe K; Meshorer E; Ast G
Cell Rep; 2015 Feb; 10(7):1122-34. PubMed ID: 25704815
[TBL] [Abstract][Full Text] [Related]
37. A polar mechanism coordinates different regions of alternative splicing within a single gene.
Fededa JP; Petrillo E; Gelfand MS; Neverov AD; Kadener S; Nogués G; Pelisch F; Baralle FE; Muro AF; Kornblihtt AR
Mol Cell; 2005 Aug; 19(3):393-404. PubMed ID: 16061185
[TBL] [Abstract][Full Text] [Related]
38. Roles of alternative splicing in modulating transcriptional regulation.
Li J; Wang Y; Rao X; Wang Y; Feng W; Liang H; Liu Y
BMC Syst Biol; 2017 Oct; 11(Suppl 5):89. PubMed ID: 28984199
[TBL] [Abstract][Full Text] [Related]
39. Single molecule analysis of c-myb alternative splicing reveals novel classifiers for precursor B-ALL.
Zhou YE; O'Rourke JP; Edwards JS; Ness SA
PLoS One; 2011; 6(8):e22880. PubMed ID: 21853052
[TBL] [Abstract][Full Text] [Related]
40. Extensive alternative splicing of the repressor element silencing transcription factor linked to cancer.
Chen GL; Miller GM
PLoS One; 2013; 8(4):e62217. PubMed ID: 23614038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
